LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX · NASDAQ Global Select
-$0.39 today
Vol 0.50M · Avg 0.23M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $320.7M |
| Short-term Investments | $45.0M |
| Other Current | $23.4M |
| Total Current Assets | $389.1M |
| PP&E (Net) | $3.6M |
| Long-term Investments | $776.0K |
| Total Non-current Assets | $4.4M |
| Total Assets | $393.5M |
Analysis
Selected assets total $393.5M for Latest. The largest visible component is Cash & Equivalents at $320.7M, about 81.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $250.2M +988.8% | $23.0M +53.4% | $15.0M -30.0% | $21.4M | $1.2B | $1.0B | $841.8M |
| Short-term Investments | $45.0M +797.0% | $5.0M -82.3% | $28.3M | $0 | -$1.7B | -$1.6B | $445.6M |
| Net Receivables | $0 | $0 | $0 | $0 | $668.2M | $533.8M | $399.4M |
| Inventory | $0 | $0 | $0 | $0 | $652.8M | $641.6M | $328.0M |
| Other Current Assets | $11.2M +8411.4% | $132.0K +407.7% | $26.0K +188.9% | $9.0K | -$1.7B | $1.5B | $966.4M |
| Total Current Assets | $308.4M +968.0% | $28.9M -36.7% | $45.6M +112.4% | $21.5M | $3.6B | $12.5B | $10.5B |
| Property, Plant & Equipment (Net) | $3.7M -10.2% | $4.2M +17973.9% | $23.0K +666.7% | $3.0K | $575.8M | $1.2B | $1.5B |
| Goodwill | $0 | $0 | $0 | $0 | $1.4B | $925.8M | $466.6M |
| Intangible Assets | $0 | $0 | $0 | $0 | $1.4B | $568.8M | $860.0M |
| Long-term Investments | $770.0K | $0 | $0 | $0 | $1.2B | $524.0M | -$1.5B |
| Tax Assets | $0 | $0 | $0 | $0 | $364.4M | $1.5B | $1.4B |
| Other Non-current Assets | $0 -100.0% | $498.0K | $0 | $0 | $1.4B | $1.4B | $1.0B |
| Total Non-current Assets | $4.5M -3.3% | $4.7M +20139.1% | $23.0K +666.7% | $3.0K | $4.7B | -$15.3B | $14.8B |
| Total Assets | $312.9M +833.2% | $33.5M -26.6% | $45.7M +112.4% | $21.5M | $14.6B | $13.3B | $11.9B |
| Account Payables | $2.1M -8.3% | $2.3M +67.0% | $1.4M +790.4% | $156.0K | $1.2B | $1.3B | -$1.5B |
| Short-term Debt | $730.0K | $0 | $0 | $0 | $1.2B | -$1.6B | -$1.6B |
| Tax Payables | $0 | $0 | $0 | $0 | $708.8M | $574.4M | -$1.5B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $340.6M | -$1.6B | $374.2M |
| Other Current Liabilities | $2.9M +29.6% | $2.2M +180.8% | $798.0K +261.1% | $221.0K | $650.0M | $1.1B | $1.5B |
| Total Current Liabilities | $7.4M -8.2% | $8.1M +211.2% | $2.6M +455.7% | $469.0K | $12.8B | $6.0B | $10.1B |
| Long-term Debt | $0 | $0 | $0 -100.0% | $24.1M | $483.4M | $1.3B | $438.6M |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $1.2B | $746.6M | $612.2M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $1.0B | -$1.6B | $715.8M |
| Other Non-current Liabilities | $1.3M -98.8% | $116.8M +50.6% | $77.5M +201.8% | $25.7M | $1.2B | $489.0M | $1.1B |
| Total Non-current Liabilities | $4.2M -96.5% | $120.0M +54.8% | $77.5M +55.6% | $49.8M | $11.3B | $3.9B | $7.5B |
| Total Liabilities | $11.6M -90.9% | $128.1M +59.9% | $80.1M +59.3% | $50.3M | $8.8B | $14.7B | $3.7B |
| Common Stock | $3.0K +200.0% | $1.0K +0.0% | $1.0K +0.0% | $1.0K | $785.8M | $651.4M | $517.0M |
| Retained Earnings | -$129.5M -24.2% | -$104.3M -153.1% | -$41.2M -18.0% | -$34.9M | $1.0B | -$1.6B | $519.8M |
| Accumulated OCI | $168.0K +51.4% | $111.0K -59.5% | $274.0K | $0 | -$1.6B | $393.8M | $550.6M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $486.2M | $351.8M | -$1.6B |
| Minority Interest | $0 | $0 | $0 | $0 | $853.0M | $1.4B | $337.8M |
| Total Equity | $301.3M +418.7% | -$94.6M -174.3% | -$34.5M -19.6% | -$28.8M | $10.4B | $9.1B | $7.7B |
| Total Debt | $3.6M -3.6% | $3.7M | $0 -100.0% | $24.1M | $735.4M | $724.2M | $410.6M |
| Net Debt | -$246.6M -1179.4% | -$19.3M -28.7% | -$15.0M -645.9% | $2.7M | -$1.7B | $389.6M | $501.6M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Design Therapeutics, Inc.
NASDAQ:DSGN
$753.86M
Solid Biosciences Inc.
NASDAQ:SLDB
$591.89M
Annexon, Inc.
NASDAQ:ANNX
$582.64M
Autolus Therapeutics plc
NASDAQ:AUTL
$411.19M
Aura Biosciences, Inc.
NASDAQ:AURA
$396.75M
DBV Technologies S.A.
NASDAQ:DBVT
$381.21M
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
$352.15M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$300.81M
Altimmune, Inc.
NASDAQ:ALT
$239.62M
Korro Bio, Inc.
NASDAQ:KRRO
$126.76M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does LBRX have?
LB Pharmaceuticals Inc Common Stock (LBRX) reported $250.17M in cash and equivalents in fiscal 2025.
How much debt does LBRX carry?
LB Pharmaceuticals Inc Common Stock (LBRX) reported $3.57M of total debt, with net debt of -$246,604,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.